|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-9-24
|
|
pubmed:abstractText |
Most patients with acute myocardial infarction (AMI) are admitted to hospitals without percutaneous transluminal coronary angioplasty (PTCA) facilities or are initially managed in a prehospital mobile unit. Thrombolysis remains the most readily available reperfusion treatment in those settings, but the optimal subsequent strategy in those patients is unclear. If a mechanical recanalization is likely to be performed in an emergency, it is probably desirable that the patient receives abciximab, the glycoprotein IIb/IIIa antagonist with the strongest evidence of benefit for angioplasty in AMI.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
pubmed-author:AiroldiFlavioF,
pubmed-author:BelpommeVanessaV,
pubmed-author:BologneseLeonardoL,
pubmed-author:Di MarioCarloC,
pubmed-author:DudekDariuszD,
pubmed-author:FlatherMarcusM,
pubmed-author:GambaratiGiampaoloG,
pubmed-author:GuiducciVincenzoV,
pubmed-author:HibonAgnes RicardAR,
pubmed-author:IndolfiCiroC,
pubmed-author:MaillardLucL,
pubmed-author:ManariAntonioA,
pubmed-author:OlivariZoranZ,
pubmed-author:PanzarasaRitaR,
pubmed-author:PatriziGiampieroG,
pubmed-author:PiovaccariGiancarloG,
pubmed-author:RusconiLuigi CesareLC,
pubmed-author:SteffeninoGiuseppeG,
pubmed-author:StegPhilippe GabrielPG,
pubmed-author:ZmudkaKrzysztofK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
148
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
378-85
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15389222-Antibodies, Monoclonal,
pubmed-meshheading:15389222-Cost-Benefit Analysis,
pubmed-meshheading:15389222-Drug Therapy, Combination,
pubmed-meshheading:15389222-Emergency Medical Services,
pubmed-meshheading:15389222-Humans,
pubmed-meshheading:15389222-Immunoglobulin Fab Fragments,
pubmed-meshheading:15389222-Myocardial Infarction,
pubmed-meshheading:15389222-Plasminogen Activators,
pubmed-meshheading:15389222-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:15389222-Prospective Studies,
pubmed-meshheading:15389222-Recombinant Proteins,
pubmed-meshheading:15389222-Recurrence,
pubmed-meshheading:15389222-Stents,
pubmed-meshheading:15389222-Thrombolytic Therapy,
pubmed-meshheading:15389222-Tissue Plasminogen Activator,
pubmed-meshheading:15389222-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
|
|
pubmed:affiliation |
Royal Brompton Hospital, London, United Kingdom. c.dimario@rbh.nthames.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
